Clinical Trial Update: A Phase II, Randomized, Double-blind, Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects With Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen [Phase 2]

View source ↗

Summary

Phase II randomized trial investigating DAS181 for parainfluenza in immunocompromised patients on supplemental oxygen has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parainfluenza Infection

Drugs mentioned

• DAS181

Snippet

Sponsor: Ansun Biopharma, Inc. | Conditions: Parainfluenza | Phase 2 | Status: COMPLETED